FY2024 Earnings Forecast for FDMT Issued By HC Wainwright

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of 4D Molecular Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($2.89) per share for the year, down from their prior forecast of ($2.59). HC Wainwright currently has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.81) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q4 2024 earnings at ($0.81) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.48) EPS and FY2028 earnings at ($3.23) EPS.

Other equities analysts have also recently issued reports about the company. Leerink Partners reaffirmed an “outperform” rating and issued a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Cantor Fitzgerald downgraded 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Chardan Capital reaffirmed a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Finally, Royal Bank of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

4D Molecular Therapeutics Trading Up 4.2 %

Shares of FDMT stock opened at $8.67 on Monday. The stock has a market cap of $400.80 million, a P/E ratio of -3.04 and a beta of 2.82. 4D Molecular Therapeutics has a 1 year low of $7.32 and a 1 year high of $36.25. The stock has a 50 day simple moving average of $10.03 and a 200 day simple moving average of $16.78.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of FDMT. Redmile Group LLC bought a new position in 4D Molecular Therapeutics in the first quarter valued at about $40,189,000. Assenagon Asset Management S.A. boosted its stake in shares of 4D Molecular Therapeutics by 238.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after purchasing an additional 1,087,147 shares in the last quarter. RA Capital Management L.P. grew its holdings in shares of 4D Molecular Therapeutics by 21.3% during the 1st quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company’s stock valued at $160,941,000 after purchasing an additional 888,300 shares during the last quarter. Braidwell LP increased its position in 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in 4D Molecular Therapeutics by 1,076.1% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 641,000 shares of the company’s stock valued at $20,422,000 after purchasing an additional 586,500 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.